Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00148902
First received: September 6, 2005
Last updated: October 6, 2008
Last verified: October 2008

September 6, 2005
October 6, 2008
April 2003
Not Provided
Safety and Tolerability
Same as current
Complete list of historical versions of study NCT00148902 on ClinicalTrials.gov Archive Site
Pharmacokinetics
Same as current
Not Provided
Not Provided
 
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)

This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumor Cancer
Drug: lapatinib and docetaxel
Other Name: lapatinib and docetaxel
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Not Provided
Not Provided

Inclusion Criteria:

  • Advanced solid tumors.
  • Able to swallow oral medication.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00148902
EGF10021
Not Provided
Study Director, GSK
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
GlaxoSmithKline
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP